Wasatch Advisors LP Takes Position in Repligen Corporation $RGEN

Wasatch Advisors LP bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 1,243,531 shares of the biotechnology company’s stock, valued at approximately $146,513,000.

Other institutional investors also recently made changes to their positions in the company. Measured Wealth Private Client Group LLC acquired a new stake in shares of Repligen during the 3rd quarter worth approximately $29,000. Bayforest Capital Ltd acquired a new position in Repligen during the 4th quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC bought a new position in Repligen during the 4th quarter worth $33,000. Los Angeles Capital Management LLC bought a new position in Repligen during the 4th quarter worth $36,000. Finally, Farther Finance Advisors LLC increased its position in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after buying an additional 128 shares during the period. 97.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on RGEN. Roth Mkm assumed coverage on Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 target price on the stock. HSBC lowered their price target on shares of Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Wolfe Research began coverage on shares of Repligen in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective on the stock. Jefferies Financial Group reiterated a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research report on Tuesday, May 5th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $164.64.

Insider Buying and Selling at Repligen

In related news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Repligen Stock Up 1.2%

RGEN opened at $147.01 on Friday. The stock’s 50 day moving average price is $122.84 and its 200 day moving average price is $135.54. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The stock has a market cap of $8.29 billion, a P/E ratio of 163.35, a P/E/G ratio of 2.80 and a beta of 1.09. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $175.77.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company had revenue of $194.25 million during the quarter, compared to analyst estimates of $192.05 million. During the same quarter in the previous year, the firm posted $0.39 EPS. The firm’s quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, research analysts predict that Repligen Corporation will post 1.99 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.